We also tested the efficacy of aldometanib on another HCC model in which Trp53 is knocked out and Myc is overexpressed, two of the most frequently altered genes in HCC patients, in the mouse liver (MYC;Trp53−/− HCC39). The gene discussed is MYC; the disease is hepatocellular carcinoma.